A shot in the arm for radiotherapy.
In this issue of Blood, Dovedi et al demonstrate convincing evidence for the therapeutic efficacy of a new systemic immunostimulatory agent, the Toll-like receptor-7 (TLR7) agonist R848, to augment radiotherapy-induced anticancer immunity.